Results · Apr-Jun 2026
Vivanza Biosciences Q1 FY27 results
Sales grew 4% to ₹9.3 crore from ₹8.9 crore in Apr-Jun 2025.
Operating profit fell 153% to −₹0.08 crore, an operating margin of −0.8% (down 2.5 points from a year ago).
Net profit grew 69% to ₹0.15 crore from ₹0.09 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +46%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 9.3 | 8.9 | +4% |
| Operating profit (EBITDA) | -0.1 | 0.1 | −153% |
| Operating margin | −0.8% | 1.7% | −2.5 pts |
| Net profit | 0.1 | 0.1 | +69% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.